Lercanidipine: New Aspects of Pathogenetic Treatment in Hypertensive Patients

V.A. Vizir, I.M. Voloshyna


The article deals with evaluation of lercanidipine impact on hemodynamic and neuroimmunological parameters in patients with essential hypertension of various additional risk, associated with obesity. It is found that long-term treatment with lercanidipine has significant effect on blood pressure level and the ability to correct the diastolic dysfunction of the left ventricle. Lercanidipine realizes its effects by increasing the plasma content of vasodilating calcitonin gene-related peptide.


essential hypertension; lercanidipine


Герасимов А.Н. Медицинская статистика / А.Н. Герасимов. — М.: Медицинское информ. агенство, 2007. — 480 с.

Рекомендації Української Асоціації кардіологів з профілактики та лікування артеріальної гіпертензії. Посібник до Національної програми профілактики і лікування артеріальної гіпертензії. — К.: ПП ВМБ, 2008. — 80 с.

Сіренко Ю.М. Гіпертонічна хвороба і артеріальні гіпертензії / Ю.М. Сіренко. — Донецьк, 2011. — 304 с.

Bang L.M. Lercanidipine: A Review of its Efficacy in the Management of Hypertension / Bang L.M., Chapman T.M., Goa K.L. // Drugs. — 2003. — Vol. 63, № 22. — Р. 2449-2472.

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients / Jamerson K., Weber M.A., Bakris G.L. [et al.] ACCOMPLISH Trial Investigators // N. Engl. J. Med. — 2008. — Vol. 359. — P. 2417-2428.

Double-blind crossover study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension / De Giorgio L.A., Orlandini F., Malasoma P. еt al. // Curr. Ther. Res. — 1999. — 60. — 511-20.

Law M.R. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies / Law M.R., Morris J.K., Wald N.J. // B.M.J. — 2009. — Vol. 338. — P. 1665-1683.

Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats / Lai Y.M., Fukuda N., Su J.Z. [et al] // Hypertens. Res. — 2002. — Vol. 25. — P. 109-115.

Telmisartan, ramipril, or both in patients at high risk for vascular events / ONTARGET Investigators: Yusuf S., Teo K.K., Pogue J. [et al.] // N. Engl. J. Med. — 2008. — Vol. 358. — P. 1547-1559.

TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II / Schultz J.E.J., Witt S.A., Glascock B.J. [et al.] // J. Clin. Invest. — 2002. — Vol. 109. — P. 787-796.

The seventh report of the Joint National Committee on prevention detection, evaluation and treatment of high blood pressure. The JNC VII Report / Chobanian A.V., Bakris G.L., Black H.R. [et al.] // JAMA. — 2003. — Vol. 289. — P. 2560-2573.

Copyright (c) 2016 HYPERTENSION

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта